transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
Company profile
Ticker
TMDX
Exchange
Website
CEO
Waleed H. Hassanein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
Subsidiaries
TransMedics, Inc. • TransMedics, B.V. • TransMedics Pty Ltd. • TransMedics GmbH • Summit Aviation, Inc. • Northside Property Group, LLC ...
TMDX stock data
Latest filings (excl ownership)
8-K
Completion of Acquisition or Disposition of Assets
12 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
6 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
29 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
2 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
19 Dec 23
8-K
Entry into a Material Definitive Agreement
13 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
TransMedics Reports Third Quarter 2023 Financial Results
6 Nov 23
Transcripts
TMDX
Earnings call transcript
2023 Q4
26 Feb 24
TMDX
Earnings call transcript
2023 Q3
6 Nov 23
TMDX
Earnings call transcript
2023 Q2
3 Aug 23
TMDX
Earnings call transcript
2023 Q1
1 May 23
TMDX
Earnings call transcript
2022 Q4
22 Feb 23
TMDX
Earnings call transcript
2022 Q3
3 Nov 22
TMDX
Earnings call transcript
2022 Q2
2 Aug 22
TMDX
Earnings call transcript
2022 Q1
4 May 22
TMDX
Earnings call transcript
2021 Q4
24 Feb 22
TMDX
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Tamer I Khayal
12 Mar 24
4
Stephen Gordon
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Tamer I Khayal
5 Mar 24
4
Stephen Gordon
5 Mar 24
4
JAMES R TOBIN
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 427.61 mm | 427.61 mm | 427.61 mm | 427.61 mm | 427.61 mm | 427.61 mm |
Cash burn (monthly) | 51.78 mm | (no burn) | 9.45 mm | 3.23 mm | 2.29 mm | 2.11 mm |
Cash used (since last report) | 307.84 mm | n/a | 56.15 mm | 19.18 mm | 13.61 mm | 12.57 mm |
Cash remaining | 119.77 mm | n/a | 371.46 mm | 408.43 mm | 414.00 mm | 415.04 mm |
Runway (months of cash) | 2.3 | n/a | 39.3 | 126.6 | 180.8 | 196.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 218 |
Opened positions | 31 |
Closed positions | 52 |
Increased positions | 93 |
Reduced positions | 66 |
13F shares | Current |
---|---|
Total value | 1.90 tn |
Total shares | 34.89 mm |
Total puts | 167.40 k |
Total calls | 498.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 4.71 mm | $258.14 bn |
BLK Blackrock | 2.45 mm | $134.10 bn |
Vanguard | 1.81 mm | $99.34 bn |
MCQEF Macquarie | 1.71 mm | $93.67 bn |
Fred Alger Management | 1.57 mm | $86.21 bn |
Allspring Global Investments | 1.27 mm | $69.62 bn |
IVZ Invesco | 1.25 mm | $68.62 bn |
Credit Suisse | 1.13 mm | $61.97 bn |
Driehaus Capital Management | 1.00 mm | $54.80 bn |
Eventide Asset Managment | 925.36 k | $50.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Stephen Gordon | Common Stock | Sell | Dispose S | No | No | 87.63 | 1,903 | 166.76 k | 23,299 |
8 Mar 24 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | No | 87.63 | 1,317 | 115.41 k | 25,185 |
8 Mar 24 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | Yes | 90.04 | 100 | 9.00 k | 26,502 |
8 Mar 24 | Tamer I Khayal | Common Stock | Option exercise | Acquire M | No | Yes | 16.14 | 100 | 1.61 k | 26,602 |
8 Mar 24 | Tamer I Khayal | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.14 | 100 | 1.61 k | 15,646 |
4 Mar 24 | Stephen Gordon | Common Stock | Sell | Dispose S | No | Yes | 82.8 | 15,000 | 1.24 mm | 25,202 |
4 Mar 24 | Stephen Gordon | Common Stock | Option exercise | Acquire M | No | Yes | 38.46 | 15,000 | 576.90 k | 40,202 |
4 Mar 24 | Stephen Gordon | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 38.46 | 15,000 | 576.90 k | 52,477 |
1 Mar 24 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | Yes | 85.18 | 1,234 | 105.11 k | 26,502 |
1 Mar 24 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | Yes | 84.26 | 424 | 35.73 k | 27,736 |
News
Jim Cramer Recommends Buying Wayfair, Says This Big Bank's Stock Yields Almost 3%
29 Feb 24
Cracking The Code: Understanding Analyst Reviews For TransMedics Gr
28 Feb 24
Morgan Stanley Maintains Equal-Weight on TransMedics Gr, Raises Price Target to $95
28 Feb 24
Organ Transplant-Focused TransMedics Clocks Q4 Profit On Increased Use Of Its Organ Care System, Analysts Optimistic About Integrated Aviation Business
27 Feb 24
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
27 Feb 24
Press releases
TMDX INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
2 Mar 24
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
1 Mar 24
TransMedics Group Investors: Company Investigated by the Portnoy Law Firm
27 Feb 24
Thinking about trading options or stock in Alphabet Inc, Autozone, Zoom Video Communications, TransMedics Group, or Viking Therapeutics?
27 Feb 24
TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm
27 Feb 24